Over the years, the hemophilia treatment landscape has transformed, with novel agents aiming to improve patient care and quality of life. Factor replacement therapy has been the standard of care in hemophilia, although there are limitations to this approach. More recently, the approval of novel gene therapies has presented a promising option for patients with both hemophilia A and B.
In this podcast, you will hear from Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, and Johannes Oldenburg, MD, University Clinic Bonn, Bonn, Germany, who discuss the current standard of care in hemophilia and share some insights into the value of gene therapies.
Understanding multiple myeloma at the single-cell level
Recent advances in amyloidosis treatment
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?
ASH 2021: novel developments in MPNs
ASH 2021: evaluating the impact of screening for multiple myeloma precursor diseases
ASH 2021: the future of cell therapies in lymphoma
ASH 2021: highlights in CLL clinical trials
ASH 2021: updates in FLT3-mutated AML
The Lymphoma Sessions: post-ASH 2021
COSTEM: maintenance therapies for FLT3+ AML
COSTEM: the role of alloHSCT in ALL
SOHO 2021: amyloidosis treatment updates
IACH 2021: CAR-T in clinical practice
Unmet needs and recent updates in CML
IMW 2021: treatment-free intervals in multiple myeloma
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.